US Patent Issued to KONINKLIJKE PHILIPS on Dec. 2 for "Post-surgical risk stratification based on PDE4D variant expression, selected according to TMPRSS2-ERG fusion status, and post-surgical clinical variables" (German Inventor)

ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,486,540, issued on Dec. 2, was assigned to KONINKLIJKE PHILIPS N.V. (Eindhoven, Netherlands).

"Post-surgical risk stratification based on PDE4D variant expression, selected according to TMPRSS2-ERG fusion status, and post-surgical clinical variables" was invented by Ralf Dieter Hoffmann (Brueggen, Germany).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to a method of post-surgical risk stratification of a prostate cancer subject, comprising determining a transmembrane protease, serine 2-ETS-related gene (TMPRSS2-ERG) fusion status in a biological sample obtained from the subject, determining a gene expression profile for each of one ...